Drugs Affecting Blood Flashcards

1
Q

Anticoagulants:
1-
2-
3-

A

Heparin
Low molecular heparins
Vitamin K antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Role of anticoagulants
1-
2-

A

Inhibit the action of coagulation factors
Interfere with the synthesis of coagulation factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Thrombin inhibtors
1-
2-

A

Heparin
LMWH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Unfractionated heparin mixture of ——
Strongly —–

A

Glycosaminoglycans (glucosamine and glucurunic acid)
Strongly acidic ( sulfate and sulfate group)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

LMWH:——-
Size:—–
Form—-

A

Enoxaparin
1/3 size of unfrationated heparin
Chemical or enzymatic depolymerization of unfractionated heparin
(Replacin heparin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Effect of heparin vs LMWH
Availability of heparin vs LMWH

A

Hep: minutes after IV vs LMWH 4 hrs
Heparin binds to many proteins that neutralize its activity thereby causing resistance to the drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

T or F
LMWH is taken up by the monocyte/macrophage system and undergo further depolymerization

A

False
Heparin and not LMWH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Excretion
Half life of each

A

Both excreted to urine (renal insufficiency prolongs half life)

Heparin 1.5 hrs
LMWH 3-7 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T or F
Heparin doesn’t cross the placenta while LMWH do.

A

False
Both don’t

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bioavailability of heparin vs LMWH
Major adverse effect of each
Setting for therapy

A

20% heparin 90% LMWH
Frequent bleeding for heparin while less frequent for LmWH
Heparin is always taken in hospital while LMWH in hospital or outpatient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Mech of action of both:

A

Binding and activating of anti thrombin III by its pentasaccharide sequence
Rapid inactivation of coagulation factors
Heparin inhibit thrombin and cofactor Xa
LMWH inhibit Xa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

T or F
Antithrombin is a serine protease

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adverse effects of both:
1-
2-
3

A

1-Bleeding: excessive may be managed by ceasing of the drug or by treating with protamine sulfate
2-Thrombosis: chronic or intermittnet adm lead to reduction in antithrombin III (low dose should be used)
3-Thrombocytopenia I: non immunologic (heparin-induced thrombocytopenia)
Thrombocytopenia II:immunoallergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

T or F
Thrombocytopenia I occur usually from 5 to 14 days

A

False
I the first 5 days
While II from 5 to 14 (replace it by other anticoagulant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Contraindications of heparin nad LMWH:
1-
2-
3-

A

Hypersensitivity
Bleeding disorders
Having a recent brain or eye surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Therapeutic uses:
1-
2-
3-

A

Acute deep vein thrombosis and pulmonary embolism
Prophylaxis to prevent venous thrombosis in oatients undergoing elective surgery and those in acute MI
Extracorporeal devices (dialysis machines)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Oral anticoagulats:
Anti-thrombin:
Anti-Xa:
1-
2-

A

Dahigatran etexilate:praxada

1- Rivaroxaban
2- Apixaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Uses of oral anti-Xa

A

For stroke prevention in atrial fibrillation

19
Q

T or F
Dabigatran etexilate is a prodrug
Used instead of enoxaparin for thrombophylaxis in orthopedic surgeries

A

T
Dabigatran is the active moiety

20
Q

Which factors need vitamin K in there synthesis?

A

II ,VII, IX ,X
They are carboxylated on their glutamic acid

21
Q

Warfarin a vitamin K antagonist results in ———, with effects observed at—— but peak effect can be delayed to —

A

Production of clotting factors with diminished activity (10-40% of normal)
8-12 hr
72-96 hrs

22
Q

Warfarin
Bioavailability:
Binding to protein:
Can be displaced by:
Half life:
Fate:

A

100%
97-99 (prevents its diffusion to CSF,urine and breast milk)
Sulfonamides
40 hrs vary among individu
Catalyzed by P450
Conjugated to glucuronic acid
Urine or stool

23
Q

Therapeutic uses of warfarin:
1-
2-
3-

A

Prevent recurrence of DVT or PE
Venous thromboembolism during orthopedic surgery
Prophylactically(acute MI,prosthetic heart valves or chronic atrial fibri)

24
Q

Adverse effects of warfarin
1-
2-
3-

A

1-bleeding disorders (INR is important)
2-minir bleeding may be treated by withrawal of the drug andmi of oral viramin K
3-severe bleeding in IV
(Whole blood, frozen plasma or plasma concentrates must be used in this case)

25
Q

Drug drug interactions

A

On slide 35

26
Q

Comtraindications

A

Because warfarin can pass through placenta it should be never given to a pregnant woman because it causes teratogenic effects or abortion as well as birth defects

27
Q

Platelet aggregation inhibitors classes
1-
2-
3-

A

1-COX-1 inhibitors
2-ADP receptors antagonists
3- GPIIbIIIa receptor antagonist

28
Q

Cox1 inhibitor named —- inhibits —– by —— of —–
The effect is (rapid/slow)—–
Suppression of platelet aggregation last for —-

A

Aspirin
Thromboxane A2
Irrevesible acetylation of serine
COX
Rapid
The life of platelet (7-10 days)

29
Q

Therapeutic uses of aspirin:
1-
2-
Recommended does:

A

Prophylactic tx of transient cerebral ischemia
To reduce the incidence of recurrent myocardial infarction
81-325 mg

30
Q

Adverse events of aspirin:
1-
2-

A

1-bleeding time is prolonged by aspirin tx causing complications that include and increased incidence of hemorrhagic stroke as well as gastrontestinal bleeding especially at higher doses of yhe drug
2-could be used in combination with other drugs having anticlotting properties (heparin) or clopidogrel

31
Q

ADP receptors antagonists:
Names
1-
2-
3-

A

Dipyridamole
Ticlopidine
Clopidogrel

32
Q

Ticlopidine and clopidogrel mech of action:
Class type:

A

Inhibit binding of ADP irrevesibly
Thus inhibit the activation of GPIIb/IIIa required for platelet to bind to fibrinogen and to each other

Thienopyridines

33
Q

Ticlopidine uses:
1-
2-

A

1-transient ischemic attacks and strokes for patients with prior cerebral thrombotic event
2-as adjunct therapy with aspirin following coronary stent implantation to decrease the incidence of stent thrombosis

34
Q

Adverse effects of ticlopidine

A

Neutropenia
Agranulocytosis
Thrombotic thrombocytopenia purpura
Aplastic anemia
(Reversed)

35
Q

Clopidogrel uses:
1-
2_

A

1-Prevention of atherosclerotic events following infarction,stroke or established peripheral atterial disease
2-prophylaxis of thrombotic events in acute coronary syndrome (unstable angina MI)

36
Q

T or F
Ticlopidine is preffered in ischemic heart disease

A

False
Reversed

37
Q

T or F
Clopidogrel has a better overall side effect profile

A

T
Lower incidence of neutropenia in clopidogrel

38
Q

Dipyridamole uses:
1-
2-
Mode of action:

A

1-coronary vasodilator (prophylactically to treat angina pectoris)
2- in combination with aspirin or warfarin (ineffective when used alone)
Increase intracellular levels of cAMP by inhibiting phosphodiesterase resulting in decreased thromboxane A2 synthesis

39
Q

GP receptors antagonist names :
1-
2-
3-

A

1-abciximab
2-eptifibatide
3-tirofiban

40
Q

Abciximab
Mode of action:
Mode of administration;
Uses:
Persistance of effect:
Adverse:

A

Monoclonal antibody directed against GP complex therefore blocking the fibrinogen binding (no agg)

IV with heparin or aspirin
Prevention of cardiac ischemic complication
24-48 hrs
Potential bleeding

41
Q

Throbolytic agents:
1-
2-
3-

A

1-Streptokinase
2-Tissue plasminogen activator (alteplase)
3-urokinase

42
Q

Mode of action of
Streptokinase
Alteplase
Urokinase

A

Systemic fibrinolysis
Activates the conversion of plasminogen into plasmin thay hydrolyzes fibrin
Enzyme synthesized in kidneys that transform plasminogen into plasmin

43
Q

T or F
Alteplase acts systemitically to produce fibrinolysis

A

False acts more locally

44
Q

Therapeutic uses:
1-
2-
3-

A

1-DVT
2-serious pulmonary embolism
3-acute MI or peripheral arterial thrombosis